ペンタゾシン

ペンタゾシン 化学構造式
359-83-1
CAS番号.
359-83-1
化学名:
ペンタゾシン
别名:
rel-(11R*)-1,2,3,4,5,6-ヘキサヒドロ-6,11-ジメチル-3-(3-メチル-2-ブテニル)-2α*,6α*-メタノ-3-ベンゾアゾシン-8-オール;ペルタゾン;ホルタリン;rac-(2R*,11R*)-1,2,3,4,5,6-ヘキサヒドロ-6,11-ジメチル-3-(3-メチル-2-ブテニル)-2α*,6α*-メタノ-3-ベンゾアゾシン-8-オール;ホルトラール;cis-(±)-ペンタゾシン;(±)-ペンタゾシン;ソセトン;ホルタルゲシック;rac-(11R*)-1,2,3,4,5,6-ヘキサヒドロ-6,11-ジメチル-3-(3-メチル-2-ブテニル)-2α*,6α*-メタノ-3-ベンゾアゾシン-8-オール;レキシル;ソセゴン;ペンタゾシン;ペンタジン;タルウィン;dl-ペンタゾシン;ヘキサット;ソシゴン;トスパリール;ペンタゾシン (JP17)
英語名:
PENTAZOCINE
英語别名:
Lexir;C07421;II-C-2;Talwan;Talwin;Fortral;KF-1820;Liticon;nih7958;sosegon
CBNumber:
CB1121418
化学式:
C19H27NO
分子量:
285.43
MOL File:
359-83-1.mol

ペンタゾシン 物理性質

融点 :
145.4-147.20C
沸点 :
427.85°C (rough estimate)
比重(密度) :
1.0104 (rough estimate)
屈折率 :
1.5180 (estimate)
闪点 :
9℃
貯蔵温度 :
Controlled Substance, -20°C Freezer
溶解性:
DMSO:>10mg/mL
酸解離定数(Pka):
pKa 8.68±0.05;11.23± 0.05(H2O,t =20,I=0.1) (Uncertain)
外見 :
個体
色:
白い
CAS データベース:
359-83-1
EPAの化学物質情報:
2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-buten-1-yl)-, (2R,6R,11R)-rel- (359-83-1)
安全性情報
  • リスクと安全性に関する声明
  • 危険有害性情報のコード(GHS)
主な危険性  Xn,T,F
Rフレーズ  22-39/23/24/25-23/24/25-11
Sフレーズ  7-16-36/37-45
RIDADR  UN1230 - class 3 - PG 2 - Methanol, solution
WGK Germany  3
RTECS 番号 PB8750000
HSコード  2933330000
有毒物質データの 359-83-1(Hazardous Substances Data)
毒性 LD50 s.c. in male rats: 175±36 mg/kg (Goldenthal)
絵表示(GHS) GHS hazard pictograms
注意喚起語 警告
危険有害性情報
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード
H302 飲み込むと有害 急性毒性、経口 4 警告 GHS hazard pictograms P264, P270, P301+P312, P330, P501
注意書き
P264 取扱い後は皮膚をよく洗うこと。
P264 取扱い後は手や顔をよく洗うこと。
P270 この製品を使用する時に、飲食または喫煙をしないこ と。
P301+P312 飲み込んだ場合:気分が悪い時は医師に連絡する こと。
P501 内容物/容器を...に廃棄すること。

ペンタゾシン 化学特性,用途語,生産方法

解説

ペンタゾシン,作用の強力な鎮痛薬の一種。白色の結晶性粉末。モルヒネなどの麻薬に拮抗(きっこう)作用があるが、これ自体にも軽度の習慣性がある。

用途

非麻薬性鎮痛薬鎮痛作用を示す

効能

鎮痛薬, オピオイド受容体作動薬/拮抗薬

商品名

ソセゴン (丸石製薬); ソセゴン (丸石製薬)

化学的特性

Crystalline Solid

使用

(?)-Pentazocine is a benzomorphan-type opiate with analgesic properties. It binds to opioid receptors (Ki values = 7.2, 31, and 5.7 nM for κ-, δ-, μ-opioid receptors, respectively) and to the type 1 σ-receptor (Kd = 12 nM). (?)-Pentazocine is abused with methylphenidate and other drugs. It is regulated as a Schedule IV compound in the United States. This product is intended for forensic and research applications.

世界保健機関(WHO)

Pentazocine, which has both agonist and weak opioid antagonist activity, was introduced in 1967 for the treatment of moderate and severe pain. The risk of drug dependence is lower with pentazocine than with morphine-like drugs and pentazocine has been controlled under Section III of the 1971 Convention on Psychotropic Substances since 1984. The risk of dependence is now widely acknowledged to exist in vulnerable individuals and at least one country has applied controls analogous to those of Schedule I of the 1961 Single Convention on Narcotic Drugs. (Reference: (UNCPS3) United Nations Convention on Psychotropic Substances (III), , , 1971)

一般的な説明

The benzomorphans are prepared synthetically and thus resultin several stereoisomers. The active benzomorphans arethose that have the equivalent bridgehead carbons in thesame absolute configuration of morphine (carbons 9, 13,and 14 of morphine). The only benzomorphan in clinical useis pentazocine, which is prepared as the 2(R), 6(R), 11(R)enantiomer (Chemical Abstracts numbering). Pentazocineis a mixed agonist/antagonist displaying differing intrinsicactivity at the opioid receptor subtypes. At the κ-receptor,pentazocine is a partial agonist and a weak antagonist.
According to the manufacturer, a 50-mg dose of pentazocinehas about the same analgesic potency as 60 mg of codeineand about 1/50th the antagonistic activity of nalorphine.74Pentazocine is also an agonist at the κ-receptor, and thismay be responsible for the higher percentage of patients thatexperience dysphoria with pentazocine versus morphine.75Some evidence also exists that women respond better to κ-agonists than men. Pentazocine is available in a 50-mgtablet along with a low dose of the antagonist naloxone 0.5mg (Talwin NX). Naloxone 0.5 mg orally is expected tohave no pharmacological effect but is included to dissuadeIV drug abusers from dissolving and injecting Talwin NX.

安全性プロファイル

Poison by ingestion, subcutaneous, intramuscular, intraperitoneal, and intravenous routes. Experimental reproductive effects. Human systemic effects by intramuscular and intravenous routes: wakefulness, euphoria, hallucinations or distorted perceptions, tremors, convulsions, excitement, motor activity changes, muscle weakness, analgesia, withdrawal, parasympathomimetic effects, nausea or vomiting, and dernlititis. Can cause drug dependency and other central nervous system effects, An analgesic. When heated to decomposition it emits toxic fumes of NOx. See also ALLIT COMPOUNDS.

ペンタゾシン 上流と下流の製品情報

原材料

準備製品

359-83-1(ペンタゾシン)キーワード:


  • 359-83-1
  • C07421
  • Pentazocine CIV (500 mg)
  • 2,6-Methano-3-benzazocin-8-ol,1,2,3,4,5,6-hexahydro-6,11-diMethyl-3-(3-Methyl-2-buten-1-yl)-,(2R,6R,11R)-rel-
  • Pentazocine solution
  • PENTAZOCINE
  • (2alpha,6alpha,11r*)-2-butenyl)
  • (2R*,6R*,11R*)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol
  • 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benza
  • 2-(3,3-Dimethylallyl)-2',2'-hydroxy-5,9-dimethyl-6,7-benzomorphan
  • 2-(3,3-dimethylallyl)-2’,2’-hydroxy-5,9-dimethyl-6,7-benzomorphan
  • 2-(3,3-Dimethylallyl)cyclazocine
  • 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-
  • 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, (2alpha,6alpha,11R)-
  • 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, (2alpha,6alpha,11R*)-
  • 2’-hydroxy-5,9-dimethyl-2-(3,3-dimethylallyl)-6,7-benzomorphan
  • 2-butenyl)-
  • 2-dimethylallyl-5,9-dimethyl-2’-hydroxybenzomorphan
  • 2-Dimethylallyl-5,9-dimethyl-2'-hydroxybenzomorphan
  • 2'-Hydroxy-5,9-dimethyl-2-(3,3-dimethylallyl)-6,7-benzomorphan
  • 3-(3-methyl-2-butenyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-2,6-methano-3-ben
  • 3-(3-methyl-2-butenyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-2,6-methano-3-benza
  • 3-(3-Methyl-2-butenyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-2,6-methano-3-benzazocin-8-ol
  • 6r*,11r*)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-(2r
  • dl-2’-hydroxy-5,9-dimethyl-2-(3,3-dimethylallyl)-6,7-benzomorphan
  • dl-2'-Hydroxy-5,9-dimethyl-2-(3,3-dimethylallyl)-6,7-benzomorphan
  • Fortalgesic
  • cis-(-Pentazocine
  • Win 2022
  • Pentazocinum
  • 1,2,3,4,5,6-Hexahydro-3-(3-methyl-2-butenyl)-6,11-dimethyl-8-hydroxy-2,6-methano-3-benzazocine
  • rel-(11R*)-1,2,3,4,5,6-ヘキサヒドロ-6,11-ジメチル-3-(3-メチル-2-ブテニル)-2α*,6α*-メタノ-3-ベンゾアゾシン-8-オール
  • ペルタゾン
  • ホルタリン
  • rac-(2R*,11R*)-1,2,3,4,5,6-ヘキサヒドロ-6,11-ジメチル-3-(3-メチル-2-ブテニル)-2α*,6α*-メタノ-3-ベンゾアゾシン-8-オール
  • ホルトラール
  • cis-(±)-ペンタゾシン
  • (±)-ペンタゾシン
  • ソセトン
  • ホルタルゲシック
  • rac-(11R*)-1,2,3,4,5,6-ヘキサヒドロ-6,11-ジメチル-3-(3-メチル-2-ブテニル)-2α*,6α*-メタノ-3-ベンゾアゾシン-8-オール
  • レキシル
  • ソセゴン
  • ペンタゾシン
  • ペンタジン
  • タルウィン
  • dl-ペンタゾシン
  • ヘキサット
  • ソシゴン
  • トスパリール
  • ペンタゾシン (JP17)
  • 麻薬拮抗薬
  • 麻薬性鎮痛薬
Copyright 2017 © ChemicalBook. All rights reserved